Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus PULMICORT FLEXHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus PULMICORT FLEXHALER.
ARMONAIR DIGIHALER vs PULMICORT FLEXHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state.
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30%
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid